argenx Framtida tillväxt
Future kriterier kontrolleras 5/6
argenx förväntas öka intäkter och intäkter med 21.6% respektive 16.9% per år. EPS förväntas tillväxt med 21.1% per år. Avkastningen på eget kapital förväntas bli 20.4% om 3 år.
Viktig information
21.6%
Tillväxttakt i vinsten
21.11%
Tillväxttakt för EPS
| Biotechs vinsttillväxt | 22.7% |
| Intäkternas tillväxttakt | 16.9% |
| Framtida avkastning på eget kapital | 20.44% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 18 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Ny berättelse • May 20
High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug
Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.
Uppdatering av berättelse • May 14
ARGX: Expanded Neuromuscular Indications Will Support Future Earnings Power
Analysts nudged their blended price target for argenx higher by about €2 to roughly €845, citing a slightly higher fair value estimate, modestly adjusted growth and discount rate assumptions, and support from recent research highlighting Vyvgart momentum and an expanded late stage pipeline. Analyst Commentary Recent research shows a split between analysts trimming targets on fine tuned assumptions and others lifting or reaffirming higher fair value estimates.
Uppdatering av berättelse • Apr 29
ARGX: Graves And gMG Franchise Expansion Will Drive Future Repricing Potential
Analysts have nudged their argenx price targets slightly lower in recent weeks, trimming individual fair values by €30 to €92. They continue to cite ongoing Vyvgart momentum, a broader late stage pipeline and a less demanding valuation as key supports for the updated outlook.Uppdatering av berättelse • Apr 15
ARGX: Late Stage Neuromuscular Readouts Will Support Future Earnings Power
Analysts have made a modest upward tweak to the fair value estimate for argenx to €842.55, reflecting updated assumptions for Vyvgart momentum, slightly higher revenue growth expectations around 26.7%, a somewhat lower profit margin near 34.7%, and a higher future P/E of about 25.5x following recent price target revisions and ongoing support from research firms despite generally lower headline targets. Analyst Commentary Recent Street research on argenx reflects generally constructive views on Vyvgart execution and the broader pipeline, with some caution around spending plans and the current valuation.Uppdatering av berättelse • Apr 01
ARGX: Graves And gMG Expansion Will Drive Future Repricing Potential
Analysts have nudged the blended price target for argenx slightly higher to about €991. This reflects updated assumptions that pair more moderate revenue growth with a higher profit margin outlook and a somewhat richer future P/E, supported by recent research citing steady Vyvgart momentum, consistent profitability and a deep late stage pipeline.Uppdatering av berättelse • Mar 17
ARGX: Late Stage Neuromuscular Pipeline Readouts Will Drive Future Upside
Argenx's updated analyst price target reflects a modest recalibration, with fair value edging from about €845 to €839 as analysts factor in ongoing Vyvgart momentum, a slightly lower future P/E assumption and continued profitability. Analyst Commentary Recent Street research on argenx clusters around two themes: execution on Vyvgart and how much of that outlook is already reflected in the share price.Uppdatering av berättelse • Mar 03
ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential
The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive.Uppdatering av berättelse • Feb 17
ARGX: Vyvgart Expansion Into Seronegative gMG Will Support Long Term Upside
Narrative Update Analysts have raised their average price target on argenx by a few euros to €825.51. This reflects updated models that incorporate slightly higher revenue growth assumptions, a modestly higher future P/E multiple and recent target increases from firms citing steady long term confidence in the story.
Uppdatering av berättelse • Feb 03
ARGX: Future Sector Correlation Risk May Undermine Elevated Biotech Thesis
Analysts have lifted their fair value estimate for argenx from US$528.05 to US$614.80, citing updated models that incorporate revised revenue growth, profit margin and future P/E assumptions, in line with a series of recent price target increases from major brokerage firms. Analyst Commentary Recent Street research on argenx has featured a series of higher price targets in both U.S. dollars and euros, reflecting updated models rather than wholesale shifts in underlying views.Uppdatering av berättelse • Jan 20
ARGX: Graves Disease And gMG Franchise Will Drive Future Repricing
Analysts have raised their fair value estimate for argenx from about $885 to roughly $990.88, citing higher modeled revenue growth assumptions, updated P/E expectations, and a series of price target increases across the Street. Analysts continue to view the company constructively, even as some lists are being rebalanced.Uppdatering av berättelse • Jan 06
ARGX: Vyvgart Franchise Expansion Will Drive Upside Despite Pipeline Setbacks
Analysts have lifted their fair value estimate for argenx from $797.32 to $820.09. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E after recent research that highlighted solid Q3 execution, optimism around Vyvgart's opportunity and some recalibration of upside potential.Uppdatering av berättelse • Dec 15
ARGX: Future Pipeline Readouts Will Balance Post Rally Expectations And Execution Risks
Analysts have nudged their average price target on argenx modestly higher by about $30 per share. This reflects stronger assumed revenue growth and higher future valuation multiples, even as they temper margin expectations in light of a more selective, probability-weighted view of the Vyvgart and empasiprubart pipelines.Uppdatering av berättelse • Nov 30
ARGX: Share Momentum Will Balance Pipeline Progress Against Post-Rally Expectations
Argenx's analyst price target has been modestly revised downward by approximately $4 to $766. Analysts are balancing optimism on new clinical data and pipeline expansion with tempered expectations following the recent stock rally.Uppdatering av berättelse • Nov 16
ARGX: Shares Will Weigh Expanding Indications Against Cooling Market Enthusiasm
Analysts have raised their price target for argenx by over $20 to approximately $770. They cite strong third-quarter performance, broadening growth drivers across Vyvgart indications, and confidence in the company’s expanding pipeline and commercial prospects.Uppdatering av berättelse • Nov 02
ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook
Argenx's analyst price target has increased by over $24 to approximately $749. Analysts cite solid quarterly results, pipeline progress, and expanded commercial opportunities as key drivers for the upward revision.Uppdatering av berättelse • Sep 25
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s consensus price target has been revised upward to €724.38 as analysts raise growth forecasts following strong Phase 3 Vyvgart data and expanding market opportunity, while improved revenue projections and robust pipeline momentum continue to offset valuation concerns. Analyst Commentary Bullish analysts are raising price targets on Argenx following positive topline Phase 3 data for Vyvgart in seronegative myasthenia gravis and successful primary endpoint achievement across patient subtypes, which expands the addressable market.Uppdatering av berättelse • Aug 29
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
argenx’s price target has been raised to €705.90 as analysts cite strong Vyvgart Phase 3 results, raised U.S. sales expectations, visible pipeline catalysts, and resilient uptake despite recent safety concerns. Analyst Commentary Bullish analysts cite Vyvgart’s positive Phase 3 ADAPT SERON results in seronegative generalized myasthenia gravis (gMG), demonstrating clinical improvement and supporting expansion into new patient subtypes.Uppdatering av berättelse • Aug 06
Aging Trends And Genomics Will Expand Autoimmune Treatment Opportunities
A sharp decline in argenx’s future P/E ratio, despite slightly lower revenue growth forecasts, has contributed to a notable increase in the consensus analyst price target from €665.23 to €700.31. What's in the News Argenx and Unnatural Products Inc.Analysartikel • Aug 01
What argenx SE's (EBR:ARGX) 25% Share Price Gain Is Not Telling You
argenx SE ( EBR:ARGX ) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Looking...Analysartikel • Jun 30
We Think argenx (EBR:ARGX) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Ny berättelse • Apr 27
Prefilled Syringe Launch And Pipeline Trials Will Expand Global Reach
Strong pipeline potential from advanced Phase III and proof-of-concept studies could drive new product approvals and market expansion, boosting revenues.Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 8,537 | 2,924 | 3,208 | N/A | 22 |
| 12/31/2027 | 7,215 | 2,416 | 3,051 | N/A | 30 |
| 12/31/2026 | 5,930 | 1,757 | 2,552 | N/A | 30 |
| 3/31/2026 | 4,742 | 1,489 | N/A | N/A | N/A |
| 12/31/2025 | 4,236 | 1,292 | 574 | 685 | N/A |
| 9/30/2025 | 3,683 | 1,533 | N/A | N/A | N/A |
| 6/30/2025 | 3,121 | 1,280 | 309 | 404 | N/A |
| 3/31/2025 | 2,643 | 1,064 | N/A | N/A | N/A |
| 12/31/2024 | 2,248 | 833 | -151 | -83 | N/A |
| 9/30/2024 | 1,909 | -40 | N/A | N/A | N/A |
| 6/30/2024 | 1,660 | -204 | -325 | -260 | N/A |
| 3/31/2024 | 1,451 | -328 | N/A | N/A | N/A |
| 12/31/2023 | 1,269 | -295 | -464 | -420 | N/A |
| 9/30/2023 | 1,029 | -234 | N/A | N/A | N/A |
| 6/30/2023 | 835 | -397 | -758 | -654 | N/A |
| 3/31/2023 | 639 | -511 | N/A | N/A | N/A |
| 12/31/2022 | 441 | -710 | -967 | -863 | N/A |
| 9/30/2022 | 286 | -909 | N/A | N/A | N/A |
| 6/30/2022 | 146 | -907 | -874 | -876 | N/A |
| 3/31/2022 | 381 | -595 | N/A | N/A | N/A |
| 12/31/2021 | 528 | -408 | -728 | -607 | N/A |
| 9/30/2021 | 510 | -373 | N/A | N/A | N/A |
| 6/30/2021 | 526 | -319 | -601 | -474 | N/A |
| 3/31/2021 | 206 | -573 | N/A | N/A | N/A |
| 12/31/2020 | 62 | -608 | -404 | -398 | N/A |
| 9/30/2020 | 75 | -535 | N/A | N/A | N/A |
| 6/30/2020 | 70 | -359 | -263 | -255 | N/A |
| 3/31/2020 | 73 | -275 | N/A | N/A | N/A |
| 12/31/2019 | 93 | -181 | N/A | 152 | N/A |
| 9/30/2019 | 72 | -109 | N/A | N/A | N/A |
| 6/30/2019 | 68 | -104 | N/A | 230 | N/A |
| 3/31/2019 | 70 | -47 | N/A | N/A | N/A |
| 12/31/2018 | 33 | -76 | N/A | -62 | N/A |
| 9/30/2018 | 41 | -56 | N/A | N/A | N/A |
| 6/30/2018 | 44 | -47 | N/A | -57 | N/A |
| 3/31/2018 | 50 | -46 | N/A | N/A | N/A |
| 12/31/2017 | 49 | -34 | N/A | -44 | N/A |
| 9/30/2017 | 42 | -30 | N/A | N/A | N/A |
| 6/30/2017 | 39 | -25 | N/A | -31 | N/A |
| 3/31/2017 | 23 | -29 | N/A | N/A | N/A |
| 12/31/2016 | 18 | -22 | N/A | 11 | N/A |
| 9/30/2016 | 17 | -20 | N/A | N/A | N/A |
| 6/30/2016 | 14 | -17 | N/A | 16 | N/A |
| 3/31/2016 | 12 | -17 | N/A | N/A | N/A |
| 12/31/2015 | 11 | -17 | N/A | -15 | N/A |
| 9/30/2015 | 10 | -16 | N/A | N/A | N/A |
| 6/30/2015 | 9 | -14 | N/A | -10 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: ARGX s prognostiserade vinsttillväxt ( 21.6% per år) är över sparkvoten ( 2.4% ).
Resultat vs marknad: ARGX s intäkter ( 21.6% per år) förväntas växa snabbare än marknaden för Belgian ( 13.2% per år).
Höga tillväxtresultat: ARGX s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: ARGX s intäkter ( 16.9% per år) förväntas växa snabbare än Belgian marknaden ( 6.7% per år).
Hög tillväxtintäkter: ARGX s intäkter ( 16.9% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: ARGX s avkastning på eget kapital förväntas bli hög om 3 år ( 20.4 %)
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 08:10 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
argenx SE bevakas av 55 analytiker. 30 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Baird |
| Colleen Kusy | Baird |
| Joel Beatty | Baird |